A5045894109- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- RNA Interference and Gene Delivery
- COVID-19 epidemiological studies
- Virus-based gene therapy research
- SARS-CoV-2 detection and testing
- COVID-19 diagnosis using AI
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Mosquito-borne diseases and control
- Phagocytosis and Immune Regulation
Institute of Human Virology
2022-2024
HIV cross-sectional surveys require multi-layered testing with several tests to estimate prevalence and HIV-1 incidence. We evaluated the performance accuracy of newly developed Triplex assay diagnose HIV-2 detect recent infections using plasma samples from 2018 Nigeria AIDS Indicator Impact Survey (NAIIS). Plasma consenting HIV-positive (n=2,773) a subset HIV-negative (n=7,196), as determined by national rapid algorithm, followed Bio-Rad Geenius HIV-1/2 Supplemental Assay Western Blot, aged...
Determining an accurate estimate of SARS-CoV-2 seroprevalence has been challenging in African countries where malaria and other pathogens are endemic. We compared the performance one single-antigen assay three multi-antigen IgG assays a Nigerian population endemic for malaria. De-identified plasma specimens from RT-PCR positive, dried blood spot (DBS) pre-pandemic negatives were used to evaluate four (Tetracore, SARS2MBA, RightSign, xMAP). Results showed higher sensitivity with (81%...
Objective There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen have shown some limitations in Africa. To assess the performance multi-antigen assay, we evaluated commercially available SARS-CoV-2 Multi-Antigen IgG assay human disease 2019 (COVID-19) Nigeria. Methods Validation xMAP was carried out using well-characterized reverse transcription polymerase chain...